Aurinia Pharmaceuticals Inc. - Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Aurinia Pharmaceuticals Inc., a foreign private issuer, on September 2, 2014. The filing serves to distribute a news release announcing that the company will begin trading on the NASDAQ Global Market.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural filing regarding a listing change and does not contain financial statements or performance data.
Material Changes
The primary material change disclosed is the commencement of trading for Aurinia Pharmaceuticals Inc. on the NASDAQ Global Market.
Guidance, Outlook, and Risks
The filing text does not provide specific guidance, outlook, management commentary, risks, contingencies, or unusual items beyond the announcement of the new trading venue.
Investor Verification Checklist
- Verify the ticker symbol and trading start time on the NASDAQ Global Market.
- Review the full news release (Exhibit 99.1) for any additional context regarding the listing.
- Consult the company's most recent Form 20-F or 40-F for detailed financial performance and risk factors.